Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
We developed a rapid in vitro antibiotic susceptibility test to screen double- and triple-antibiotic combinations for bactericidal activity against 75 multiresistant Pseudomonas aeruginosa isolates referred from 44 cystic fibrosis (CF) patients. When used alone, the most effective intravenous antibiotic, meropenem, was bactericidal against only 44% of the isolates. High-dose tobramycin (200 microg/ml; concentrations achievable by aerosol administration) was bactericidal against 72% of isolates. Adding a second antibiotic significantly improved bactericidal activity. The most effective double-antibiotic combinations contained high-dose tobramycin plus meropenem, piperacillin/tazobactam, or ciprofloxacin, and were bactericidal against 88 to 94% of the isolates. Excluding high-dose tobramycin, the most effective intravenous double-antibiotic combinations contained meropenem plus ciprofloxacin, tobramycin (4 microg/ml), or cefipime, and were bactericidal against 85%, 71%, and 70% of isolates, respectively. Adding a third antibiotic did not significantly improve inhibition in vitro. We conclude that double-antibiotic combinations containing meropenem or high-dose tobramycin show the best bactericidal activity in vitro against multiresistant strains of P. aeruginosa. Addition of a third antibiotic to these double-antibiotic combinations may be unnecessary.
Lang
B J
BJ
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Aaron
S D
SD
Ferris
W
W
Hebert
P C
PC
MacDonald
N E
NE
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology*; D004305:Dose-Response Relationship, Drug; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D024841:Fluoroquinolones; D006801:Humans; D007769:Lactams; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000706:statistics & numerical data; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D013997:Time Factors
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007769:Lactams